---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014866"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:54.778695+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024

## Summary
- Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.
- Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.
- LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.
- NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.
- Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing.

## SEC filing metadata
- accession: 0001558370-24-014866
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/0001558370-24-014866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/nxtc-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014866
- JSON: https://secwatch.observer/filing/0001558370-24-014866.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.